Neil Desai (@ndesai2005) 's Twitter Profile
Neil Desai

@ndesai2005

Radiation oncologist in GU malignancies, father and low skill/high enthusiasm DIY’er. Views are my own. @UTSW

ID: 3519683472

calendar_today10-09-2015 21:47:29

1,1K Tweet

1,1K Followers

379 Following

Giulio Francolini (@giuliofrancoli1) 's Twitter Profile Photo

📢💉HCUCG trial: The addition of Nivolumab into trimodality therapy for non metastatic bladder cancer marked a significant improvement in OS and BDFFS.☢️☢️,ESTRO ,#ESTRO25

📢💉HCUCG trial: The addition of Nivolumab into trimodality therapy for non metastatic bladder cancer marked a significant improvement in OS and BDFFS.☢️☢️,<a href="/ESTRO_RT/">ESTRO</a> ,#ESTRO25
Neil Desai (@ndesai2005) 's Twitter Profile Photo

@RaguRatnakumaran Alison Tree 💙 PACE-B GU tox data analyzed in depth and well discussed - no clear bladder/urethra correlate or below Rx, Important selection factor of baseline IPSS, and highlights challenge comparing physician graded GU tox when med patterns vary #ESTRO2025

@RaguRatnakumaran <a href="/alison_tree/">Alison Tree 💙</a>  PACE-B GU tox data analyzed in depth and well discussed - no clear bladder/urethra correlate or below Rx, Important selection factor of baseline IPSS, and highlights challenge comparing physician graded GU tox when med patterns vary #ESTRO2025
Neil Desai (@ndesai2005) 's Twitter Profile Photo

Dr Lucas Mendez @ #ESTRO2025 primary analysis of HOPE RCT n=80 of 25/5 vs CFRT for EBRT following HDR in PCa- no clear urinary/bowel qol diff at median 27mo f/u. 1 gr3 GU (turp) in 25/5 arm. Impt data as limited adoption w single arm studies even while 5 fx sbrt mono now an SOC

Dr Lucas Mendez @ #ESTRO2025 primary analysis of HOPE RCT n=80 of 25/5 vs CFRT for EBRT following HDR in PCa- no clear urinary/bowel qol diff at median 27mo f/u. 1 gr3 GU (turp) in 25/5 arm. Impt data as limited adoption w single arm studies even while 5 fx sbrt mono now an SOC
ROBIN OligoMET Center (@robinoligometc) 's Twitter Profile Photo

We are pleased to share our recent #publication in Journal of Clinical Oncology titled, “Outcomes of Radium-223 & Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial” Read on: ascopubs.org/doi/10.1200/JC…

Shankar Siva (@_shankarsiva) 's Twitter Profile Photo

🚀 New in Journal of Clinical Oncology - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048

Daniel E Spratt (@drspratticus) 's Twitter Profile Photo

Proud Chair moment. The incredible Angela Jia representing RadOncUH on the big stage of #asco25 as the discussant to two big hitting presentations ASCO Thoughtful analysis of benefit (or not of) intraprostatic immune modulating viral therapy and the role of MMAI in

Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

After our daughter Ceci died at 15 mo of a paraspinal tumor, we’ve been committed to supporting pediatric cancer research. We’re honored this year's Cattle Baron’s Ball will establish Ceci’s Fund through the American Cancer Society. Please share/donate💕 cattlebaronsball.com

After our daughter Ceci died at 15 mo of a paraspinal tumor, we’ve been committed to supporting pediatric cancer research.

We’re honored this year's Cattle Baron’s Ball will establish Ceci’s Fund through the American Cancer Society.

Please share/donate💕
cattlebaronsball.com
Tian Zhang, MD, MHS (@tiansterzhang) 's Twitter Profile Photo

Last week Dr. Andy Wang 🇺🇦 & I published 1st of our translational research in #MolecularCancer BMC, developing a multifunctional immunotherapy nanoparticle (MINP) to treat #kidneycancer. Thanks to #KinmanAu & #SiqingLi, 2 of our postdocs UTSW Simmons Cancer Center who did the work. 1/n